[
    [
        {
            "time": "2023-11-22",
            "original_text": "小而美“隐形冠军”：A股细分行业龙头股一览",
            "features": {
                "keywords": [
                    "隐形冠军",
                    "A股",
                    "细分行业",
                    "龙头股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "小而美“隐形冠军”：A股细分行业龙头股一览",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "恒瑞、信达、君实、百济PD-1谁的销量高？谁能取胜药价谈判？谁的适应症多？谁进治疗指南多？PD-(L)1价格战已在途！",
            "features": {
                "keywords": [
                    "恒瑞",
                    "信达",
                    "君实",
                    "百济",
                    "PD-1",
                    "药价谈判",
                    "适应症",
                    "治疗指南",
                    "价格战"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞、信达、君实、百济PD-1谁的销量高？谁能取胜药价谈判？谁的适应症多？谁进治疗指南多？PD-(L)1价格战已在途！",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "医保“黑名单”标准划定，指望“既往不咎”就大错特错了",
            "features": {
                "keywords": [
                    "医保",
                    "黑名单",
                    "既往不咎"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医保“黑名单”标准划定，指望“既往不咎”就大错特错了",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "6只股获北向资金连续净买入",
            "features": {
                "keywords": [
                    "北向资金",
                    "净买入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "6只股获北向资金连续净买入",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "陆股通净买入超百亿元，连续3日净买入",
            "features": {
                "keywords": [
                    "陆股通",
                    "净买入",
                    "百亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "陆股通净买入超百亿元，连续3日净买入",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "新一轮国家医保谈判启动在即 PD-1再次成焦点 恒瑞、百济望加入角逐",
            "features": {
                "keywords": [
                    "医保谈判",
                    "PD-1",
                    "恒瑞",
                    "百济"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新一轮国家医保谈判启动在即 PD-1再次成焦点 恒瑞、百济望加入角逐",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-22",
            "original_text": "400亿创新药龙头逆势大跌 北上资金抄底这些医药股 连续下跌",
            "features": {
                "keywords": [
                    "创新药",
                    "龙头",
                    "北上资金",
                    "抄底",
                    "医药股",
                    "连续下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "400亿创新药龙头逆势大跌 北上资金抄底这些医药股 连续下跌",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]